[Depakine in the therapy of epilepsy in children and adolescents].
The study included 642 patients, aged from 2 months to 18 years, who received different forms of depakine during the period from 2000 to 2006. Also the treatment with injection form of depakine was analyzed in 14 children. The drug was assessed in mono- and polytherapy. All patients underwent online EEG and MRI monitoring of the brain. Video EEG monitoring was conducted according to plasma concentration level of valproate. The best therapeutic effect was found for idiopathic partial epilepsy. The complete stopping of seizures was observed in 71% of patients from this group. The treatment of idiopathic generalized forms of epilepsy led to stable remission in 64%. In 23% of patients with symptomatic partial epilepsy, 100% efficacy of depakine in the monotherapy was achieved. It has been suggested that depakine is highly effective and tolerable for most of the patients and can be recommended as a drug of choice for all forms of epilepsy in children and adolescents. The use of injection form is effective for stopping of epileptic status.
Guzeva
V I
VI
Fomina
M Iu
MIu
Korostovtsev
D D
DD
Guzeva
V V
VV
Guzeva
O V
OV
D000293:Adolescent; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008279:Magnetic Resonance Imaging; D008297:Male; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014635:Valproic Acid / Q000008:administration & dosage / Q000627:therapeutic use*
D000927:Anticonvulsants; D014635:Valproic Acid